Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Acquired by C WorldWide Group Holding A S

C WorldWide Group Holding A S lifted its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 33.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 400,000 shares of the company’s stock after purchasing an additional 100,000 shares during the period. C WorldWide Group Holding A S’s holdings in Ionis Pharmaceuticals were worth $13,984,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in IONS. Creative Planning raised its position in shares of Ionis Pharmaceuticals by 5.7% during the 3rd quarter. Creative Planning now owns 28,382 shares of the company’s stock valued at $1,137,000 after buying an additional 1,522 shares during the period. International Assets Investment Management LLC raised its position in Ionis Pharmaceuticals by 3,287.0% in the third quarter. International Assets Investment Management LLC now owns 328,772 shares of the company’s stock valued at $13,171,000 after purchasing an additional 319,065 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in Ionis Pharmaceuticals by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,288 shares of the company’s stock valued at $216,000 after purchasing an additional 930 shares during the period. abrdn plc raised its position in Ionis Pharmaceuticals by 22.8% in the third quarter. abrdn plc now owns 303,274 shares of the company’s stock valued at $12,064,000 after purchasing an additional 56,357 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Ionis Pharmaceuticals by 64.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 28,121 shares of the company’s stock worth $1,127,000 after acquiring an additional 10,971 shares in the last quarter. 93.86% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Patrick R. O’neil sold 6,165 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $31.62, for a total transaction of $194,937.30. Following the completion of the sale, the executive vice president now directly owns 57,452 shares in the company, valued at approximately $1,816,632.24. This trade represents a 9.69 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Michael R. Hayden purchased 5,000 shares of Ionis Pharmaceuticals stock in a transaction dated Monday, December 23rd. The shares were bought at an average price of $36.22 per share, with a total value of $181,100.00. Following the completion of the transaction, the director now owns 35,219 shares in the company, valued at approximately $1,275,632.18. This trade represents a 16.55 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders sold 110,609 shares of company stock worth $3,564,867. Company insiders own 2.71% of the company’s stock.

Ionis Pharmaceuticals Price Performance

Shares of NASDAQ:IONS opened at $32.33 on Monday. The company has a quick ratio of 8.82, a current ratio of 8.47 and a debt-to-equity ratio of 2.12. The company has a market cap of $5.14 billion, a P/E ratio of -10.63 and a beta of 0.34. Ionis Pharmaceuticals, Inc. has a 52 week low of $30.23 and a 52 week high of $52.34. The company has a 50-day moving average price of $33.65 and a 200 day moving average price of $38.24.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings data on Wednesday, February 19th. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.46. The firm had revenue of $227.00 million during the quarter, compared to the consensus estimate of $140.97 million. Ionis Pharmaceuticals had a negative net margin of 64.25% and a negative return on equity of 100.05%. The firm’s revenue was down 30.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.12 earnings per share. Research analysts predict that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Citigroup dropped their price target on shares of Ionis Pharmaceuticals from $67.00 to $64.00 and set a “buy” rating for the company in a research note on Thursday. StockNews.com downgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th. William Blair restated an “outperform” rating on shares of Ionis Pharmaceuticals in a research note on Friday, December 20th. BMO Capital Markets decreased their price objective on shares of Ionis Pharmaceuticals from $60.00 to $45.00 and set a “market perform” rating for the company in a research note on Thursday. Finally, Needham & Company LLC restated a “buy” rating and issued a $60.00 price objective on shares of Ionis Pharmaceuticals in a research note on Thursday. Two analysts have rated the stock with a sell rating, five have issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Ionis Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $60.00.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.